ZAGAM
LOE ApproachingNDAORALTABLET
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZAGAM is an oral tablet small-molecule antibiotic approved in December 1996 by Viatris. The drug's specific indication, mechanism of action, and pharmacologic class are not detailed in available data, but it represents a legacy anti-infective in the oral formulation portfolio. ZAGAM is positioned as a standard-of-care option in its therapeutic area.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100), signaling declining team investment and potential portfolio transition roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZAGAM offers limited career growth due to its approaching loss-of-exclusivity status and minimal linked job openings (0 current roles). Career value lies primarily in defensive brand management, market access optimization, and cost-containment strategies rather than expansion or innovation.
Brand ManagerProduct Manager
Worked on ZAGAM at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.